lexpress.fr
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
- How do the varying costs of Wegovy and Mounjaro across French pharmacies impact patient access and treatment adherence?
- The recent expansion of access to Wegovy and Mounjaro in France, allowing prescriptions from general practitioners and for a wider BMI range, has fueled a surge in online services. These range from illegal online sales to legitimate telehealth platforms offering remote consultations and personalized support programs. The absence of public funding creates price disparities and raises concerns about patient safety and access equity.
- What are the immediate consequences of the expanded access to Wegovy and Mounjaro in France, considering the lack of public funding and the resulting market dynamics?
- As of late June 2025, fewer than 40,000 French citizens used new anti-obesity medications (Wegovy and Mounjaro), despite expanded access since June 23rd. This limited uptake contrasts with the 1.6 million British users, highlighting a significant difference in market penetration. The lack of public funding in France contributes to high price variability, ranging from €120 to €468 monthly.
- What are the long-term implications of the current unregulated market for anti-obesity medications in France, and what measures could ensure both patient safety and equitable access?
- The unregulated market for anti-obesity medications in France presents significant challenges. The absence of reimbursement leads to substantial price variations, potentially limiting access for many. Simultaneously, the rise of online services, while offering convenience, raises concerns regarding patient safety and efficacy due to risks of counterfeit drugs and inadequate monitoring. Future regulatory actions and research evaluating digital support programs are crucial.
Cognitive Concepts
Framing Bias
The article's framing leans towards highlighting the risks and challenges associated with the widespread availability of anti-obesity medications. The headline (while not provided) likely focuses on the concerns rather than the potential positive effects. The introductory paragraph emphasizes the slow initial uptake and the subsequent concerns of specialists, setting a cautious tone from the beginning. This emphasis on the negative aspects could potentially shape public perception negatively, downplaying the potential benefits of the medication.
Language Bias
The article generally maintains a neutral tone, but some language choices could be considered slightly loaded. For example, phrases like "aiguise déjà l'appétit de nombreux acteurs" (sharpen the appetite of many actors) and "l'échec et l'abandon de traitement guettent" (failure and abandonment of treatment are lurking) carry negative connotations. More neutral alternatives could be used to describe the market expansion and the potential for treatment failure.
Bias by Omission
The article focuses primarily on the challenges and risks associated with the new anti-obesity medications, such as price variations, illegal online sales, and insufficient patient monitoring. While it mentions the benefits and efficacy of the medications, it doesn't delve into the potential long-term positive impacts on public health or the economic benefits of reduced obesity-related healthcare costs. The perspectives of patients who have successfully used the medication and experienced positive outcomes are largely absent.
False Dichotomy
The article presents a somewhat false dichotomy between the potentially beneficial aspects of online support services and the dangers of unregulated online sales. While acknowledging that some online services offer helpful support, it strongly emphasizes the risks associated with unregulated options, potentially overshadowing the potential benefits of convenient and accessible online support for patients in remote areas or with mobility issues.
Sustainable Development Goals
The article discusses the introduction of new anti-obesity medications (Wegovy and Mounjaro) in France, potentially improving the health and well-being of obese individuals. However, it also highlights concerns about unequal access, pricing variations, and the emergence of unregulated online services, which could negatively impact the effectiveness and safety of the treatment. The positive impact stems from the availability of effective treatments, while the negative aspects relate to accessibility and safety issues.